Oxaliplatin (NSC 266046)

Catalog No.S1224 Synonyms: L-OHP, Eloxatin

For research use only.

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Oxaliplatin (NSC 266046) Chemical Structure

CAS No. 61825-94-3

Selleck's Oxaliplatin (NSC 266046) has been cited by 139 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Other DNA/RNA Synthesis Products

Biological Activity

Description Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[9]
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Caco2 MVTGeY5kfGmxbjDBd5NigQ>? NUjSWoltOzBxMUCwxsDPxE1? M3XxXFE3yqCq M3TadGROW09? MYHhZ5RqfmG2ZYOgUpJnOg>? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3NkSxOUc,OjR3NU[0NVU9N2F-
Caco2  M3G5VGZ2dmO2aX;uJGF{e2G7 NWLLWI5COy9zMD:zNEDPxE1? M13s[|E3KGh? NW[xNHN4TE2VTx?= MV3pcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBCU1JzQ{GsJG5SVzFuIFjPMVEtKE2UUEKsxsBidmSPUmCzxsBld3OnLXTldIVv\GWwdHz5 M4G4O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW2OFE2Lz5{NEW1OlQyPTxxYU6=
Caco2  M4PIcmZ2dmO2aX;uJGF{e2G7 MofiN|DDqM7:TR?= NVrJSIlpOjRiaB?= NVzqcYdpTE2VTx?= NGPzWpZqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGhQNTFuIFHLVlFENCCjbnSgUnFQOQ>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3NkSxOUc,OjR3NU[0NVU9N2F-
SW620 M1rMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTMNVAuPzBibXevUC=> NH3TRpAzPC92OD:3NkBp Mm\pbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NEHEdXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0OlMxPSd-MkS2OFY{ODV:L3G+
SW480  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjSN5B6PDhiaNMg MoHSTWM2OD1{MD64JJVoN22O NFnXR2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyNFY4PSd-MkS3NlA3PzV:L3G+
HCT116 MoPmSpVv[3Srb36gRZN{[Xl? NEjZcGwzNzViwsXN NH\iZWgzPC92ODDo NUDLNW15e3WycILld5NmeyC|dYL2bZZqdiCvUl7BJIV5eHKnc4Ppc44> NYTTNW14RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlE1OTFpPkK0O|YyPDFzPD;hQi=>
HT-29 M1\MSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXpc|EyyqEQvF2= NU\aboMzOC15MjDo M3\BOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz NFzM[JA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
SW480 MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH2V5d[OcLizszN NEDMRYQxNTd{IHi= NFXHd3pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NEKxUXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
HUVEC MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fPV2lEPTB;MUGuN|DDqMLzwrCxMlAzKM7:TR?= NVPnR2M5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
HEK293 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTI[FJKSzVyPUiuPFLDqMLzwrC1MlU6KM7:TR?= M{TmWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
HT-29 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkKxTWM2OD53MDFOwG0> NUn5UY11RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
HCT-116 NFKyNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC2NmpKSzVyPU[uNlTDqMLzwrCyMlk4KM7:TR?= NVO5SXFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
MCF-7 NWPK[mx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTF2LkK0xsDDucLiMT64NkDPxE1? M3XBOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
HepG2 M3e5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDPTWM2OD1zND6yOOKhyrIEoEGuPFIh|ryP NWn3eFk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
A549 NFPWfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm4[XF6UUN3ME21NU4xQMLiwsJCpFExNjl4IN88US=> NIHFdGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO|Q1QCd-MkWzNFc1PDh:L3G+
SGC7901 NHfrN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{exeGlEPTB;MkGuO|PDqMLzwrCzMlA5KM7:TR?= MoPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
COC1 M2fHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zjcmlEPTB;NE[uNlDDqMLzwrCzMlE1KM7:TR?= NY\zd3lbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
HCT116  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfaSYs4OiCqwrC= MkjYTWM2OD14LkKzxtExNjd3INM1[{9uVA>? MlXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|NkC2N|EoRjJ3M{[wOlMyRC:jPh?=
SW480 M{H6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVe3NkBpyqB? NEfFeIVKSzVyPUGwMlfDuTJwMk[gxtVoN22O MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4ME[zNUc,OjV|NkC2N|E9N2F-
MIAPaCa-2 Mkj3SpVv[3Srb36gRZN{[Xl? MmrpNlXjiIoEtV2= NFzRXWgzPC92ODDo NUD1WI9scW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zxsA> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
Panc-1 NFz4RVdHfW6ldHnvckBCe3OjeR?= NIW1R3ozPeLCidM1US=> NUW4VIhyOjRxNEigbC=> MmXSbY5lfWOnczDjcIVifmGpZTDv[kBRSVKSLDDjZZNx[XOnLUmsJINie3Cjc3WtPEBidmRiY3HzdIF{\S1|wrC= M1nTZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
MIAPaCa-2 MVTBdI9xfG:|aYOgRZN{[Xl? MlvDNlXjiIoEtV2= NIr5e5MzPCCq MXPpcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC NFrteGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OFkyPCd-MkW0OFQ6OTR:L3G+
Panc-1 MYDBdI9xfG:|aYOgRZN{[Xl? MoPQNlXjiIoEtV2= NHfwd|EzPCCq NWK4SFVXcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= MnzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
HPDE M4XBZ2NmdGxiVnnhZoltcXS7IFHzd4F6 Mo[2NlUwPTBizszN NIDMXoEzPC92ODDo NXO1cIlYcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD M{LsO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
SW1990 NIjvT21E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4mxOFI2NzVyIN88US=> NGDLVXozPC92ODDo MmmzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MmDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
MIAPaCa-2 M1\6fGNmdGxiVnnhZoltcXS7IFHzd4F6 MXqyOU82OCEQvF2= NHHxcoUzPC92ODDo M37mPYlvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NV3MS45URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
Panc-1 MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFXu[HIzPS93MDFOwG0> M4S1ZlI1NzR6IHi= NY\RUmg5cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD NHjMSnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OFkyPCd-MkW0OFQ6OTR:L3G+
A549/CDDP NHe3N2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fOXWlEPTB;MUiuOkDDuSBzLkKg{txO NED1[VE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVI1Oyd-MkW2NlUzPDN:L3G+
A549 NFroTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvMUGhKSzVyPUWuPEDDuSByLk[g{txO MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NUK0N{c,OjV4MkWyOFM9N2F-
SW480 M3GxU2Z2dmO2aX;uJGF{e2G7 MWOxNQKBkcL3Zz;tcC=> NVPmVJNyOjUkgJno MW\lcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? M2PSOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
SW620 MUDGeY5kfGmxbjDBd5NigQ>? M1r1WVEx6oDLwsXnM41t MkTCNlTjiImq NX;FXHpE\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4 M360VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
SW480 MYfGeY5kfGmxbjDBd5NigQ>? M4PXPVEx6oDLwsXnM41t NGrqbJUzPOLCiXi= NEfNUYlqdmO{ZXHz[ZMhVEN|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w MmXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEm0NlAoRjJ3N{S5OFIxRC:jPh?=
SW620 M3fTbGZ2dmO2aX;uJGF{e2G7 M2H3TlEx6oDLwsXnM41t MoPINlTjiImq NVvudHlXcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= Ml\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEm0NlAoRjJ3N{S5OFIxRC:jPh?=
HT-29 M1rud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;FTWM2OD13LkKyJO69VQ>? M1LpWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
SNU-175 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjNUo42UUN3ME2xMlUyKM7:TR?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUS3PUc,OjV5NkG0O|k9N2F-
COLO-320DM M1rsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDFRVFzUUN3ME21MlM5KM7:TR?= M4rjZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
DLD-1 M{H6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zGUWlEPTB;OD62OUDPxE1? NEPsVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
DiFi MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFyLkm1JO69VQ>? M4fBUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
HCT-15 M{\yUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\ufmlEPTB;OD62OEDPxE1? MnmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O|koRjJ3N{[xOFc6RC:jPh?=
SCM-1 NGnPSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfhb5JKSzVyPUG3MlUh|ryP MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd6OUC1O{c,OjV5OEmwOVc9N2F-
TMK-1 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LC[WlEPTB;MkKuOkDPxE1? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd6OUC1O{c,OjV5OEmwOVc9N2F-
MKN-45 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrQTWM2OD1zND6wJO69VQ>? MkDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
AGS NGLvcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\RTWM2OD1zMD62JO69VQ>? NIrVV2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
S3 NFTYOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm2e|hKSzVyPUWzMlUhyrFiMT61JO69VQ>? NYHTNnZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFExODdpPkK1PFAyODB5PD;hQi=>
SiHa NV;veXZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v2TmlEPTB;MD64JOKyKDBwMTFOwG0> NGfMfXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwNVAxPyd-MkW4NFExODd:L3G+
HT-29 MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T1dmlEPTB;M{WuOkDPxE1? NFrOWHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwN|A5PSd-Mk[wNFMxQDV:L3G+
DLD-1 NHzTUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTN{LkKg{txO MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByM{C4OUc,OjZyMEOwPFU9N2F-
HT29 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmezTWM2OD14MzFOwG0hyrFiMUi= MnzRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMESwPFQoRjJ4MEC0NFg1RC:jPh?=
MC38 NXzoT3hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ|IN88UUDDuSB{ MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNEC4OEc,OjZyMESwPFQ9N2F-
SW620 NIHvUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHsfodzUUN3ME2zMlY5KM7:TR?= Mn[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
SW480 NVjR[JNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJwOE[g{txO MlHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
RKO M3XmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnF[|NKSzVyPUGuNlMh|ryP M1q3RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
LoVo MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HhS2lEPTB;MT6yJO69VQ>? NFKxeHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
KM12 M2nsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLQVHdKSzVyPUSuN|ch|ryP M3rTRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
HCT116p53- MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwMEig{txO NWHGN5JnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
HCT116 NULa[pY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwMESg{txO NXj1c2RsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
HCT15 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ztR2lEPTB;MT60N{DPxE1? NEDMToQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
HT29 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXwTWM2OD1{Lk[5JO69VQ>? NVG4Um1TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
DLD1 MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nlVmlEPTB;Mj6wNUDPxE1? NELORnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
Colo205 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLoTWM2OD1|LkOzJO69VQ>? MmW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
BE NXzuWI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDCTWM2OD1|LkOzJO69VQ>? M32zVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
CT26  NGj0[mZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3fo[|QhdU1? MkfsOFghcMLi NW\RN|g6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRwKDV|LkKl M2fybVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NFEzLz5{NkGzO|AyOjxxYU6=
CT26  MmPSSpVv[3Srb36gRZN{[Xl? NVLkfmFYPCCvTR?= MYO0PEBpyqB? M4C1Zolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gZZV1d3CqYXf5MZJmdGG2ZXSgdJJwfGWrboOsJJN2[2hiYYOgUGM{NUmLLDDC[YNtcW5zIHHu[EBCXEd3 Mn7DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{ewNVIoRjJ4MUO3NFEzRC:jPh?=
CT26  NXrYOlQ6TnWwY4Tpc44hSXO|YYm= M37KNFQhdU1? M{DOXVQ5KGkEoB?= NIrNepJqdmS3Y3XzJIF2fG:yaHHnfS=> NYr6N3VIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|cxOTJpPkK2NVM4ODF{PD;hQi=>
SK-OV-3 MknsSpVv[3Srb36gRZN{[Xl? MoXZOVAh|ryPwrC= MWS0PEBpyqB? NF\0[Jdxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> NEfodXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
OVCAR-5 M3rZPGZ2dmO2aX;uJGF{e2G7 MW[yNEDPxE4EoB?= NF\MOXgzPGh? NGP1VnFxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> NU\seYR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
PA-1 MlLqSpVv[3Srb36gRZN{[Xl? NX32XXZvOTBizszNxsA> Ml\pNlRp NVrPeXMyeHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> NXrtfmdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
SK-OV-3 M1\KTGZ2dmO2aX;uJGF{e2G7 MYK1NEDPxE1? NH\xVW06PiCq Ml:yeZAuemWpdXzheIV{KHSqZTDzeJJme3NibHnnZY5leyCob4KgUmsh[2WubD3hZ5RqfmG2aX7nJJJm[2WydH;yd{BidmRiVGLBTWwhemWlZYD0c5J{ NHjhcXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
OVCAR-5 NIjFPHhHfW6ldHnvckBCe3OjeR?= M4nSO|MxKM7:TR?= NYPr[40{PDiq NWnNXXA3fXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| NHvYbXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
PA-1 NGrFcZJHfW6ldHnvckBCe3OjeR?= MYKxNEDPxE4EoB?= MXK0PIg> MYr1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> NU\sdnFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
SK-OV-3 MnzlSpVv[3Srb36gRZN{[Xl? NH7F[|Q2OCEQvF2= M{DpWFk3KGh? NEXhSGN1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> MnrEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
OVCAR-5 M2jiPGZ2dmO2aX;uJGF{e2G7 NYL5[ldNOzBizszN NW\YN5dWPDiq NH3l[3Z1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> NX\1emtyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
PA-1 MlLsSpVv[3Srb36gRZN{[Xl? MX[xNEDPxE4EoB?= NIP5O2szPGh? M3XZc5RzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> NWmwNmI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
SK-OV-3 MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoLYNE0yODBizszN M3TNS|I1NzR6L{eyJIg> NVjtT5NOcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
OVCAR-5 NGX4eGJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYr3bpRWOC14MDFOwG0> MoT0NlQwPDhxN{KgbC=> NGL1cY5qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MkDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
PA-1 M1flUGNmdGxiVnnhZoltcXS7IFHzd4F6 MXKwMVIxKM7:TR?= Ml7DNlQwPDhiaB?= M1TwWIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NVSzVGltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
HCT116 NUHINHB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfaTWM2OD1yLkSxxsDDucLiMD6wNkDPxE1? NX3LS2hPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOFg2QTZpPkK2NVQ5PTl4PD;hQi=>
HT29 Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L5SWlEPTB;MD64POKhyrIEoECuNkDPxE1? NUXl[4lCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOFg2QTZpPkK2NVQ5PTl4PD;hQi=>
SNU-387 M17nW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnSV29wUUN3ME2yOeKhyrIEoEKuO{DPxE1? NVjJRVY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlA1OjlpPkK2NVYxPDJ7PD;hQi=>
SNU-475 NXKzNmxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|Ux97zgM{Cg{txO MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4MESyPUc,OjZzNkC0Nlk9N2F-
Hep-G2 MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu4eXBbUUN3ME2xN{4yyqEEsdMgNU43KM7:TR?= NXnHd2liRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlA1OjlpPkK2NVYxPDJ7PD;hQi=>
SNU-398 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;zWWlEPTB;Nj61xsDDucLiMT6xJO69VQ>? M2DVfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[wOFI6Lz5{NkG2NFQzQTxxYU6=
LoVo  NGLvXHBHfW6ldHnvckBCe3OjeR?= Ml3UNU82KM7:TR?= MUSyOE81QCCq M4PIUIlv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= NYHjV4ttRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFg2OjNpPkK2NlA5PTJ|PD;hQi=>
HCT116 p53+/+ MkHZSpVv[3Srb36gRZN{[Xl? NHfEcoIyNzVizszN NInIZ5YzPC92ODDo NHP2UGVqdmS3Y3XzJJRz[W6|Y4LpdJRqd26jbDDy[ZBz\XO|aX;uJI9nKESXVD3O M2LzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkC4OVI{Lz5{NkKwPFUzOzxxYU6=
MDA-MB-231 M2nu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPHclFMUUN3ME2yN{4yKMLzIECuNUDPxE1? M1mzelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGxOVkyLz5{NkKxNVU6OTxxYU6=
MCF-7 NXLmO4ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17WRWlEPTB;MUWuOEDDuSByLkOg{txO M4OxR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGxOVkyLz5{NkKxNVU6OTxxYU6=
SK-BR-3 NUP0[5FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTNzLkCgxtEhOC5zIN88US=> MoXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUG1PVEoRjJ4MkGxOVkyRC:jPh?=
LoVo MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nGR|Q5KGkEoB?= NXG2O|BnUUN3ME25OE45OyEQvF2= M4jXT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mk[5O|U6Lz5{NkK2PVc2QTxxYU6=
HCT116 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[0PEBpyqB? M2XSdmlEPTB;MUGuPFYh|ryP NVzoNGNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOlk4PTlpPkK2NlY6PzV7PD;hQi=>
SW480 NY\5XnpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjTSZc1QCCqwrC= NFz6NGxKSzVyPUGuPFch|ryP NV3zSFVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOlk4PTlpPkK2NlY6PzV7PD;hQi=>
CaES-17 Mn\1R5l1d3SxeHnjbZR6KEG|c3H5 MWiw5qCUOTZywrFOwG0> MlvOOFjDqGh? MmS4TWM2OD13LkZCpOKyyqByLkKg{txO M172Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEe0Olk{Lz5{NkS3OFY6OzxxYU6=
HKESC-2 MYHDfZRwfG:6aXPpeJkhSXO|YYm= M1XwPFDjiJNzNkFCpO69VQ>? MUO0POKhcA>? M3fp[2lEPTB;NT64xsDDucLiMD61JO69VQ>? M1LJT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEe0Olk{Lz5{NkS3OFY6OzxxYU6=
Assay
Methods Test Index PMID
Western blot VEGFR-1 / NRP-1 ; p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416) ; p-Src(Y418) / p-FAK(Y861) 18790786 19383922
Immunofluorescence E-cadherin / Vimentin ; ATXN2L / G3BP1 30787271
Growth inhibition assay Cell viability 28339092
In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol (from reference)

Cell Research:

[4]

  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control

  • (Only for Reference)
Animal Research:

[6]

  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
  • (Only for Reference)

Solubility (25°C)

In vitro

Water 3 mg/mL warmed
(7.55 mM)
DMF Insoluble
Ethanol ''0.01 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage 2 years 4°C(in the dark) powder
Smiles C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05025826 Not yet recruiting Other: Phycocare|Other: Placebo Metastatic Gastric Cancer Nantes University Hospital|Algosource November 5 2021 Not Applicable
NCT05031975 Not yet recruiting Drug: Irinotecan|Drug: Temozolomide Colorectal Cancer Fondazione IRCCS Istituto Nazionale dei Tumori Milano November 1 2021 Phase 2
NCT05068531 Not yet recruiting -- Colorectal Cancer Metastatic Centre hospitalier de l''Université de Montréal (CHUM)|Exactis Innovation|Chaire Roger Des Groseillers d''oncologie chirurgicale HBP de l''Université de Montréal|Canexia Health October 2021 --
NCT04158349 Terminated Drug: Oxaliplatin|Drug: mFOLFIRI Colorectal Cancer|Appendiceal Cancer|Peritoneal Carcinoma University of Utah March 22 2021 Phase 1
NCT04944550 Recruiting -- Upper Urinary Tract Urothelial Carcinoma|Nephroureterectomy|Tumor|Xenograft Model Centre Hospitalier Universitaire de Nīmes|INSERM U1194 Institut de Recherche en Cancérologie de Montpellier Campus Val d''Aurelle 34298 Montpellier cedex 5 March 1 2021 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Is it ok to dissolve Oxaliplatin in DMSO?

Answer:
Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

Tags: buy Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) supplier | purchase Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) cost | Oxaliplatin (NSC 266046) manufacturer | order Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) distributor